Search Results
Your search for Fred Saad, MD, FRCS,Fred Saad, MD, FRCS matches 4 pages
Showing 1 - 4Patient-Reported Outcomes With the Addition of Olaparib to Abiraterone in Castration-Resistant Prostate Cancer
As reported in The Lancet Oncology by Fred Saad, MD, FRCS, and colleagues, an analysis of a phase II trial found no significant differences in health-related quality of life or pain measures with the addition of olaparib to abiraterone in patients with metastatic castration-resistant prostate...
ACIS Trial: Addition of Apalutamide to Abiraterone Acetate/Prednisone for Metastatic Castration-Resistant Prostate Cancer
As reported in The Lancet Oncology by Fred Saad, MD, FRCS, and colleagues, the phase III ACIS trial has shown that the addition of apalutamide to abiraterone acetate and prednisone significantly prolonged radiographic progression–free survival in men with metastatic castration-resistant prostate...
TITAN Trial: Apalutamide Adds to Options for Men With Metastatic Hormone-Sensitive Prostate Cancer
Androgen-deprivation therapy has been, and remains, the standard of care for patients with metastatic prostate cancer. Patients are often surprised to learn that was all we would do to control their disease and sometimes asked why they would not receive chemotherapy, as for other cancers. I would...
TITAN Trial: Apalutamide Adds to Options for Men With Metastatic Hormone-Sensitive Prostate Cancer
Androgen-deprivation therapy has been, and remains, the standard of care for patients with metastatic prostate cancer. Patients are often surprised to know that was all we would do to control their disease and sometimes asked why they would not get chemotherapy, as for other cancers. I would take...
